Statins may be useful in diabetic foot ulceration treatment and prevention

Medical Hypotheses

Volumn 69, Issue 6, 2007, Pages 1313-1315

  Gulcan, Erim ^a   Gulcan, Aynur ^a   Erbilen, Enver ^a   Toker, Serdar ^a  

^a DUMLUPINAR UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NERVE GROWTH FACTOR; NITRIC OXIDE; POLYOL; PROTEIN KINASE C INHIBITOR; STATINE DERIVATIVE; VASODILATOR AGENT;

ARTICLE; BLOOD VESSEL REACTIVITY; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; COST OF ILLNESS; DIABETIC FOOT; DIABETIC NEUROPATHY; DIABETIC PATIENT; DOWN REGULATION; FRACTURE HEALING; GLYCOSYLATION; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INFECTION; ISCHEMIA; LEG AMPUTATION; MICROCIRCULATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SCIATIC NERVE; SYNTHESIS; TREATMENT RESPONSE; UPREGULATION; VASCULAR DISEASE; VASOCONSTRICTION; VASODILATATION;

AMPUTATION; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEUROPATHIES; FOOT ULCER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIA; MODELS, THEORETICAL;

ANIMALIA; MURINAE;

EID: 35448947523     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.03.022     Document Type: Article

References (31)

1. Pinzur MS, Diabetic foot. http;//www.emedicine.com/orthoped/topic387.htm, June 2, 2004.
2. Cameron N.E., Eaton S.E., and Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44 (2001) 1973-1988
3. Gianni C., and Dyck P.J. Basement membrane thickening and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol 37 (1995) 498-504
4. Britland S.T., Young R.J., Sharma A.K., et al. Relationship of endoneurial capillary abnormalities to type and severity of diabetic neuropathy. Diabetes 39 (1990) 909-913
5. Timperley W.R., Ward J.D., Preston F.E., et al. Clinical and histological studies in diabetic neuropathy. Diabetologia 12 3 (1976) 237-243
6. Sheetz M.J., and King G.L. Molecular under-standing of hyperglycemia's adverse effects for diabetic complications. JAMA 288 (2002) 2579-2588
7. Duby J.J., Campbell R.K., Seter S.M., White J.R., and Rasmussen K.A. Diabetic neuropathy: an intensive review. Am J Health-Syst Pharm 61 2 (2004) 160-176
8. Yamagishi S., Nakamura K., Matsui T., Sato T., and Takeuchi M. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Med Hypotheses 66 5 (2006) 1019-1021 Epub 2005 Sep 26
9. Li M., Nishimura H., Kusano K.F., Oin G., Yoon Y.S., Wecker A., et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 112 1 (2005) 93-102
10. Leiter L.A. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?. Diabetes Res Clin Prac 68 Suppl. 2 (2005) S3-S14
11. Nangle M.R., Cotter M.A., and Cameron N.E. Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes 52 9 (2003) 2396-2402
12. Fried L.F., Forrest K.Y., Ellis D., Chang Y., Silvers N., and Orchard T.J. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complicat 15 3 (2001) 113-119
13. Sowers J.R. Effect of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am J Cardiol 91 Suppl. (2003) 14-22
14. Laufs U., and Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthasr mRNA stability by RhoGTPase. J Biol Chem 273 (1998) 24266-24271
15. Kaesemayer W.H., Caldwell R.B., Huang J., and Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 33 (1999) 234-241
16. Mital S., Zhang X., Zhao G., Bernstein R.D., Smith C.J., Fulton D.L., et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol 279 (2000) 2649-2657
17. Alverez De Sotomayor M., Herrera M.D., Marhuenda E., and Andriantsitohaina R. Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat. Brit J Pharmacol 131 (2000) 1179-1187
18. Amin-Hanjani S., Staglio N.O., Yanmada M., Huang P.L., Liao J.K., and Moskowitz M.A. Mavastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32 (2001) 980-986
19. Herna'ndez-Perera O., Pe'rez-sala D., Navarro-Antolin J., Sanchez-Pascuala R., Herna'ndez G., Diaz C., et al. Effects of the 3-hydroxy-3-methylglutaryl CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin 1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
20. van der Harst P., Wagenaar L.J., Buikema H., Voors A.A., Plokker H.W., Morshuis W.J., et al. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin 2 in stable coronary artery disease. Am J Cardiol 96 10 (2005) 1361-1364
21. 2+ channel expression in endothelial cells. Biochem Biophys Res Commun 347 2 (2006) 394-400
22. Chudzik W., Kaczorowska B., Chmielewski H., Przybyla M., and Gakla M. Statins and stroke. Pol Merkur Lekarski 19 112 (2005) 591-595
23. Rossiello M.R., Momi S., Caracchini R., Giannini S., Guglielmini G., Monopoli A., et al. A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J Thromb Haemost 3 11 (2005) 2554-2562
24. Vasa M., Fichtlscherer S., Adler K., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 (2001) 2885-2890
25. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 14 (1993) 977-986
26. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 9131 (1998) 837-853
27. Klein R., Klein B.E., Moss S.E., and Cruickshanks K.J. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 154 19 (1994) 2169-2178
28. Schalkwi{dotless}jk C.G., and Stehouwer C.D. A.Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci 109 (2005) 143-159 (Printed in Great Britain)
29. Adah F., Benghuzzi H., Tucci M., Russell G., Tsao A., Olivier J., et al. Evaluation of the male reproductive organs after treatment with continuous sustained delivery of statin for fracture healing. Biomed Sci Instrum 41 (2005) 54-61
30. Wong R.W., and Rabie A.B. Early healing pattern of statin-induced osteogenesis. Brit J Oral Max Surg 43 1 (2005) 46-50
31. Skoglund B., Forslund C., and Aspenberg P. Simvastatin improves fracture healing in mice. J Bone Miner Res 17 11 (2002) 2004-2008